Business
Jaguar Health Reports 2021 Third Quarter Financial Results
Mytesi® prescription volume increased 7.6% in Q3 2021 over Q2 2021Third quarter 2021 Mytesi net and gross sales were approximately $0.6 million and
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Mytesi® prescription volume increased 7.6% in Q3 2021 over Q2 2021Third quarter 2021 Mytesi net and gross sales were approximately $0.6 million and approximately $3.2 millionCompany expects to complete transition to selling Mytesi through closed specialty pharmacy network by end of 2021 as part of Company's market access strategyUpcoming December 2021 milestones: Presentation of Phase 2 HALT-D study results at San Antonio Breast Cancer Symposium & launch of Canalevia™-CA1 for chemotherapy-induced diarrhea in dogsREMINDER: Jaguar to host investor webcast today (Wednesday, November 17th) at 8:30 a.m. Eastern regarding third quarter 2021 financials & business updates; Click here to register for webcastSAN FRANCISCO, CA / ACCESSWIRE / November 17, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today reported consolidated third quarter 2021 financial results.Mytesi (crofelemer) prescription volume, the metric the Company believes to be the best indicator of patient demand, increased 7.6% in the third quarter of 2021 over the second quarter of 2021, and new Mytesi prescriptions increased 9.0% during the same period. Mytesi total prescription volume remained the same in the third quarter of 2021 over the third quarter of 2020 and new Mytesi prescriptions increased by 10.5% during the same period. Prescription volume differs from invoiced sales volume.As previously announced, the Company is in the process of transitioning a substantial amount of Mytesi volume to a closed network of specialty pharmacies (rather than to wholesalers that resell the product to retail pharmacies) by the end of 2021. This transition results in an underrepresentation of Mytesi utilization, as revenue related to wholesaler inventory has already been recognized by Jaguar, and that inventory has now been brought down. A key component of the Company's market access strategy, this initiative is intended to help remove access barriers for patients receiving Mytesi, and includes services such as a higher level of support for prior authorizations, appeals, adherence counseling, and home delivery options. While patients often visit retail pharmacies for short-term or uncomplicated medical needs, specialty pharmacies focus on serving patients with complex and chronic medical conditions like HIV. The transition to a closed network of specialty p...